OncoMatch/Clinical Trials/NCT06083922
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Is NCT06083922 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Cyclophosphamide and Bortezomib for multiple myeloma.
Treatment: Cyclophosphamide · Bortezomib · Dexamethasone · Daratumumab — The purpose of this study is to find out whether cyclophosphamide, bortezomib, dexamethasone (CyBorD) with daratumumab SC is a safe treatment combination for MGRS-associated kidney disease including cast nephropathy associated with multiple myeloma. In addition, the researchers will find out whether the study drug combination is an effective treatment for these conditions.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: drugs aimed at the plasma cell dyscrasia
Treatment with prior drugs aimed at the plasma cell dyscrasia
Cannot have received: investigational agents aimed at the plasma cell dyscrasia
Treatment with prior or concurrent investigational agents aimed at the plasma cell dyscrasia
Cannot have received: chemotherapy
Chemotherapy ≤ 14 days of registration
Cannot have received: investigational drug or invasive investigational medical device
Exposure to an investigational drug (including investigational vaccine) or invasive investigational medical device for any indication within 4 weeks or 5 pharmacokinetic halflives, whichever is longer
Lab requirements
Blood counts
Neutrophils ≥ 1.0 × 10^9 /L (no G-CSF/GM-CSF within 1 week or pegfilgrastim within 2 weeks of screening); Platelets ≥ 100 × 10^9 /L for run-in and 75 × 10^9 /L for phase II (no platelet support); hemoglobin ≥ 7.5 g/dL without prior RBC transfusion within 7 days before the laboratory test; recombinant human erythropoietin use is permitted
Kidney function
eGFR < 40 ml/min/1.73m2 or 24h urine total protein > 1gm
Liver function
AST, AP, or ALT ≤ 3 × ULN; total bilirubin ≤ 1.5 × ULN except for patients with a history of elevated total bilirubin, such as in Gilbert's; Hepatic Child-Pugh score at worse A (patients with Child-Pugh B or C excluded, A excluded from Run-in-Period)
adequate hematology laboratory values... adequate hepatic function laboratory values ≤ 14 days prior to registration
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Tufts Medical Center (Data Collection Only) · Boston, Massachusetts
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities) · Commack, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify